Genzyme Diagnostics Forgoes Access to Future Syn-X Technologies in Effort to Resolve Dispute | GenomeWeb

NEW YORK, July 11 – Genzyme Diagnostics no longer has first offer rights to future technologies developed by Syn-X Pharma, following an agreement that resolves previous disputes between the two companies.

In a statement issued on Tuesday, Genzyme and Syn-X announced that Genzyme would continue to develop a stroke panel called NeuroTrak, while Syn-X would retain rights to future royalty payments based on product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.